AVROBIO, Inc. AVRO
Set alert
1.40 +1.40 —
Day range unavailable
52-week range unavailable
- Open
- —
- Prev close
- 0.00
- Mkt cap
- 5.24M
- Vol
- 0
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- —
- High
- —
- Forward P/E
- -8.24
- Beta
- 1.22
- Short ratio
- 0.70
- Inst. own
- 0.00%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 8, 2024
- 50-d avg
- 16.17
- 200-d avg
- 16.46
- 1y target
- 2.00
Key statistics
- Market cap
- 5.24M
- Enterprise value
- -27.41M
- Trailing P/E
- 0.17
- Forward P/E
- -8.24
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.06
- EPS (TTM)
- 8.28
- Beta
- 1.22
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 0.00%
- Revenue (TTM)
- 0
- Revenue growth
- 0.00%
- Free cash flow
- -30.75M
- Total cash
- 90.48M
- Total debt
- 224.00K
- Return on equity
- 42.73%
- Shares outstanding
- 3.74M
- Short % of float
- 0.45%
- 50-day average
- 16.17
- 200-day average
- 16.46
Analyst view
Consensus: hold
Hold
Price target (mean) 2.00
Ratings (0m) 4 4 buy · 0 hold · 0 sell
- Strong buy2
- Buy2
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.08.
Financials — quick view
AVRO Revenue — quarterly 0
AVRO Net income — quarterly -6.81M
AVRO EPS — quarterly -0.15
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Aug 8, 2024 | Jun 1, 2024 | 0.00 | — | — | — |
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Mar 14, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 9, 2023 | Sep 1, 2023 | -0.23 | — | — | — |
| Aug 10, 2023 | Jun 1, 2023 | 1.35 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | -0.56 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Jul 12, 2023 | Wells Fargo | main | Overweight | Overweight |
| Jul 11, 2023 | Wedbush | down | Outperform | Neutral |
| Mar 23, 2023 | Mizuho | main | — | Buy |
| Mar 23, 2023 | Needham | reit | — | Buy |
| Dec 7, 2022 | BTIG | up | Neutral | Buy |
| May 16, 2022 | Needham | main | — | Buy |
About AVROBIO, Inc.
AVROBIO, Inc., a clinical-stage gene therapy company, develops hematopoietic stem cell gene therapies to treat rare diseases in the United States. Its gene therapies employ hematopoietic stem cells that are harvested from the patient and then modified with a lentiviral vector to insert the equivalent of a functional copy of the gene that is mutated in the target disease. The company's pipeline includes AVR-RD-02, which is in phase 1/2 clinical trial for the treatment of Gaucher disease type 1 and 3; AVR-RD-01, which is in phase 2 clinical trials for the treatment of Fabry disease; and AVR-RD-03 that is in preclinical stage for the treatment of Pompe disease. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- avrobio.com
News
- Why Is Avrobio (AVRO) Stock Moving Today?
- Tectonic Therapeutic Appoints Daniel Lochner as Chief Financial Officer
- AVROBIO INVESTOR ALERT BY THE FORMER ATTORNEY GENERAL OF LOUISIANA: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
- AVROBIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AVROBIO, Inc. - AVRO
- Shareholder Alert: Ademi LLP investigates whether AVROBIO, Inc. has obtained a Fair Price in its transaction with Tectonic
- AVRO Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of AVROBIO, Inc. Is Fair to Shareholders
- AVROBIO and Tectonic Therapeutic Announce Merger
- Is AVROBIO (AVRO) Stock Outpacing Its Medical Peers This Year?
- Is AVROBIO (AVRO) Outperforming Other Medical Stocks This Year?
- Has AVROBIO (AVRO) Outpaced Other Medical Stocks This Year?
Your note
Sign in to keep a note on AVRO — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ATLAS VENTURE FUND LP | Director | Purchase | Jul 18, 2019 | 0 |
| AVRUCH STEVEN N. J.D. | Officer | Conversion of Exercise of derivative security | Jan 31, 2024 | 22,022 |
| DONENBERG PHILLIP BRIAN | Director | Purchase | Feb 16, 2021 | 2,000 |
| GOLIPOUR AZADEH | Chief Technology Officer | Conversion of Exercise of derivative security | Jan 31, 2024 | 55,872 |
| LEONARD BRADEN MICHAEL | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 13, 2024 | 0 |
| MACKAY GEOFFREY | Chief Executive Officer | Conversion of Exercise of derivative security | Jan 23, 2023 | 778,343 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 10.20% | 4,541,381 | 4.31M | Jun 29, 2023 |
| Tang Capital Management, LLC | 6.07% | 2,705,000 | 2.57M | Jun 29, 2023 |
| GMT Capital Corp | 5.42% | 2,412,015 | 2.29M | Jun 29, 2023 |
| Acadian Asset Management. LLC | 3.98% | 1,770,147 | 1.68M | Jun 29, 2023 |
| Vanguard Group Inc | 2.65% | 1,181,134 | 1.12M | Jun 29, 2023 |
| Morgan Stanley | 2.36% | 1,049,270 | 996.91K | Jun 29, 2023 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 1.42% | 630,579 | 599.11K | Jun 29, 2023 |
| Vanguard Extended Market Index Fund | 1.21% | 537,481 | 510.66K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.50% | 223,158 | 245.47K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.22% | 96,000 | 91.21K | Jun 29, 2023 |
| Fidelity Total Market Index Fund | 0.11% | 47,959 | 52.75K | May 30, 2023 |
| Fidelity Series Total Market Index Fund | 0.09% | 42,141 | 46.35K | May 30, 2023 |